Positron emitting tracers in pre-clinical drug development

Current Radiopharmaceuticals

Volumn 5, Issue 2, 2012, Pages 90-98

  Fernandes, E ^a   Barbosa, Z ^a   Clemente, G ^b   Alves, F ^a,b   Abrunhosa, A J ^b,c  

^a POLYTECHNIC INSTITUTE OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Animal models; Drug development; Molecular imaging; PET; Pre clinical; Radiopharmaceuticals

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; BROMINE 76; CARBON 11; CHOLINE C 11; CISPLATIN N 13; COPPER 64; CYCLIN DEPENDENT KINASE INHIBITOR; DASATINIB F 18; DOCETAXEL C 11; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUCICLOVINE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROTAMOXIFEN F 18; GADOTERIC ACID; GALLIUM 68; GEFITINIB; GLYCOPROTEIN P; IODINE 124; LIPOCORTIN 5; MULTIDRUG RESISTANCE PROTEIN; NITROGEN 13; OXYGEN 15; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

APOPTOSIS; CARDIOLOGY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TARGETING; INFLAMMATORY DISEASE; MOLECULAR IMAGING; MOLECULAR INTERACTION; NEUROLOGY; NEUROSCIENCE; NONHUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ELECTRONS; HEART DISEASES; INFLAMMATION; NEOPLASMS; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84857135421     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011205020090     Document Type: Review

References (75)

1. Eckelman, W.C. The use of PET and knockout mice in the drug discovery process. Drug Discov. Today, 2003, 8(9), 404-410.
2. Mozley, P.D. Weaving single photon imaging into new drug development. Mol. Imaging Biol., 2005, 7(1), 30-36.
3. Pien, H.H.; Fischman, A.J.; Thrall, J.H.; Sorensen, A.G. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today, 2005, 10(4), 259-266.
4. DiMasi, J.A.; Hansen, R.W.; Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ., 2003, 22(2), 151-185.
5. Murgo, A.J.; Kummar, S.; Rubinstein, L.; Gutierrez, M.; Collins, J.; Kinders, R.; Parchment, R.E.; Ji, J.; Steinberg, S.M.; Yang, S.X.; Hollingshead, M.; Chen, A.; Helman, L.; Wiltrout, R.; Tomaszewski, J.E.; Doroshow, J.H. Designing phase 0 cancer clinical trials. Clin. Cancer Res., 2008, 14(12), 3675-3682.
6. Kinders, R.; Parchment, R.E.; Ji, J.; Kummar, S.; Murgo, A.J.; Gutierrez, M.; Collins, J.; Rubinstein, L.; Pickeral, O.; Steinberg, S.M.; Yang, S.; Hollingshead, M.; Chen, A.; Helman, L.; Wiltrout, R.; Simpson, M.; Tomaszewski, J.E.; Doroshow, J.H. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol. Interv., 2007, 7(6), 325-334.
7. Smith, S.V. Molecular imaging with copper-64. J. Inorg. Biochem., 2004, 98(11), 1874-1901.
8. Disselhorst, J.A.; Brom, M.; Laverman, P.; Slump, C.H.; Boerman, O.C.; Oyen, W.J.; Gotthardt, M.; Visser, E.P. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J. Nucl. Med., 2010, 51(4), 610-617.
9. Gross, S.; Piwnica-Worms, D. Molecular imaging strategies for drug discovery and development. Curr. Opin. Chem. Biol., 2006, 10(4), 334-342.
10. Rudin, M.; Rausch, M.; Stoeckli, M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol. Imaging Biol., 2005, 7(1), 5-13.
11. Rudin, M. Noninvasive structural, functional, and molecular imaging in drug development. Curr. Opin. Chem. Biol., 2009, 13(3), 360-371.
12. Seo, Y. Quantification of SPECT and PET for drug development. Current radiopharmaceuticals, 2008, 1, 17-21.
13. Gomes, C.M.; Abrunhosa, A.J.; Ramos, P.; Pauwels, E.K. Molecular imaging with SPECT as a tool for drug development. Adv. Drug Deliv. Rev., 2010,
14. Saleem, A.; Aboagye, E.O.; Matthews, J.C.; Price, P.M. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother. Pharmacol., 2008, 61(5), 865-873.
15. Van den Abbeele, A.D.; Badawi, R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer, 2002, 38 Suppl 5, S60-S65.
16. Oka, S.; Hattori, R.; Kurosaki, F.; Toyama, M.; Williams, L.A.; Yu, W.; Votaw, J.R.; Yoshida, Y.; Goodman, M.M.; Ito, O. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J. Nucl. Med., 2007, 48(1), 46-55.
17. Schuster, D.M.; Nye, J.A.; Nieh, P.T.; Votaw, J.R.; Halkar, R.K.; Issa, M.M.; Yu, W.; Sepulveda, J.; Zeng, W.; Young, A.; Goodman, M.M. Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) with PET in renal carcinoma. Mol. Imaging Biol., 2009, 11(6), 434-438.
18. Weber, W.A. Monitoring tumor response to therapy with 18F-FLT PET. J. Nucl. Med., 2010, 51(6), 841-844.
19. Solomon, B.; Binns, D.; Roselt, P.; Weibe, L.I.; McArthur, G.A.; Cullinane, C.; Hicks, R.J. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol. Cancer Ther., 2005, 4(9), 1417-1422.
20. Cai, W.; Rao, J.; Gambhir, S.S.; Chen, X. How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther., 2006, 5(11), 2624-2633.
21. Prior, J.O.; Montemurro, M.; Orcurto, M.V.; Michielin, O.; Luthi, F.; Benhattar, J.; Guillou, L.; Elsig, V.; Stupp, R.; Delaloye, A.B.; Leyvraz, S. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J. Clin. Oncol., 2009, 27(3), 439-445.
22. Boss, D.S.; Olmos, R.V.; Sinaasappel, M.; Beijnen, J.H.; Schellens, J.H. Application of PET/CT in the development of novel anticancer drugs. Oncologist., 2008, 13(1), 25-38.
23. Larson, S.M. Cancer drug development with the help of radiopharmaceuticals: academic experience. Curr. Pharm. Des, 2009, 15(9), 950-956.
24. Sun, Y.Y.; Chen, Y. Cancer drug development using glucose metabolism radiopharmaceuticals. Curr. Pharm. Des, 2009, 15(9), 983-987.
25. Stroobants, S.; Goeminne, J.; Seegers, M.; Dimitrijevic, S.; Dupont, P.; Nuyts, J.; Martens, M.; van den Borne, B.; Cole, P.; Sciot, R.; Dumez, H.; Silberman, S.; Mortelmans, L.; van, O.A. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer, 2003, 39(14), 2012-2020.
26. Bystrom, P.; Berglund, A.; Garske, U.; Jacobsson, H.; Sundin, A.; Nygren, P.; Frodin, J.E.; Glimelius, B. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-Dglucose positron emission tomography in patients with advanced colorectal cancer. Ann. Oncol., 2009, 20(6), 1057-1061.
27. Wang, J.; Maurer, L. Positron Emission Tomography: applications in drug discovery and drug development. Curr. Top. Med. Chem., 2005, 5(11), 1053-1075.
28. Chen, W.; Delaloye, S.; Silverman, D.H.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.; Phelps, M.E.; Cloughesy, T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol., 2007, 25(30), 4714-4721.
29. Liu, G.e.al. Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib. Journal of Clinical Oncology, 2008, 26(15 supplement),
30. Hara, T.; Kosaka, N.; Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med., 1998, 39(6), 990-995.
31. Hara, T. 18F-fluorocholine: a new oncologic PET tracer. J. Nucl. Med., 2001, 42(12), 1815-1817.
32. Schmid, D.T.; John, H.; Zweifel, R.; Cservenyak, T.; Westera, G.; Goerres, G.W.; von Schulthess, G.K.; Hany, T.F. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology, 2005, 235(2), 623-628.
33. Murphy, P.S.; Bergstrom, M. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. Curr. Pharm. Des, 2009, 15(9), 957-965.
34. Hoebers, F.J.; Kartachova, M.; de, B.J.; van den Brekel, M.W.; van, T.H.; van, H.M.; Rasch, C.R.; Valdes Olmos, R.A.; Verheij, M. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(3), 509-518.
35. Haubner, R.; Weber, W.A.; Beer, A.J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K.F.; Goebel, M.; Hein, R.; Wester, H.J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS. Med., 2005, 2(3), e70-
36. Abourbeh, G.; Dissoki, S.; Jacobson, O.; Litchi, A.; Ben, D.R.; Laki, D.; Levitzki, A.; Mishani, E. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl. Med. Biol., 2007, 34(1), 55-70.
37. Dehdashti, F.; Flanagan, F.L.; Mortimer, J.E.; Katzenellenbogen, J.A.; Welch, M.J.; Siegel, B.A. Positron emission tomographic assessment of metabolic flare to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med., 1999, 26(1), 51-56.
38. Dehdashti, F.; Mortimer, J.E.; Trinkaus, K.; Naughton, M.J.; Ellis, M.; Katzenellenbogen, J.A.; Welch, M.J.; Siegel, B.A. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res. Treat., 2009, 113(3), 509-517.
39. Luurtsema, G.; Molthoff, C.F.; Windhorst, A.D.; Smit, J.W.; Keizer, H.; Boellaard, R.; Lammertsma, A.A.; Franssen, E.J. (R)-and (S)-[11C]verapamil as PET-tracers for measuring Pglycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol., 2003, 30(7), 747-751.
40. Saleem, A.; Harte, R.J.; Matthews, J.C.; Osman, S.; Brady, F.; Luthra, S.K.; Brown, G.D.; Bleehen, N.; Connors, T.; Jones, T.; Price, P.M.; Aboagye, E.O. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J. Clin. Oncol., 2001, 19(5), 1421-1429.
41. Moehler, M.; Dimitrakopoulou-Strauss, A.; Gutzler, F.; Raeth, U.; Strauss, L.G.; Stremmel, W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer, 1998, 83(2), 245-253.
42. Gupta, N.; Price, P.M.; Aboagye, E.O. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur. J. Cancer, 2002, 38(16), 2094-2107.
43. van der Veldt, A.A.; Lammertsma, A.A.; Hendrikse, N.H. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin. Cancer Res., 2007, 13(24), 7522-7523.
44. Ukkonen, H.; Yoshinaga, K.; DaSilva, J.N.; Beanlands, R.S.; Knuuti, J. Cardiovascular drug development using radiopharmaceuticals. Curr. Pharm. Des, 2009, 15(9), 935-942.
45. Paans, A.M.; Vaalburg, W. Positron emission tomography in drug development and drug evaluation. Curr. Pharm. Des, 2000, 6(16), 1583-1591.
46. Aboagye, E.O.; Price, P.M.; Jones, T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov. Today, 2001, 6(6), 293-302.
47. Hasegawa, S.; Yamamoto, K.; Sakata, Y.; Takeda, Y.; Kajimoto, K.; Kanai, Y.; Hori, M.; Hatazawa, J. Effects of cardiac energy efficiency in diastolic heart failure: assessment with positron emission tomography with 11C-acetate. Hypertens. Res., 2008, 31(6), 1157-1162.
48. Riemann, B.; Schafers, K.P.; Schober, O.; Schafers, M. Small animal PET in preclinical studies: opportunities and challenges. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(3), 215-221.
49. Tuunanen, H.; Engblom, E.; Naum, A.; Nagren, K.; Scheinin, M.; Hesse, B.; Juhani Airaksinen, K.E.; Nuutila, P.; Iozzo, P.; Ukkonen, H.; Opie, L.H.; Knuuti, J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation, 2008, 118(12), 1250-1258.
50. Talbot, P.S.; Laruelle, M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol., 2002, 12(6), 503-511.
51. Lever, J.R. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. Curr. Pharm. Des, 2007, 13(1), 33-49.
52. Hargreaves, R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther., 2008, 83(2), 349-353.
53. Brooks, D.J. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx., 2005, 2(2), 226-236.
54. Miller, J.M. Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development. Current radiopharmaceuticals, 2008, (1), 12-16.
55. Bakhtiar, R. Biomarkers in drug discovery and development. J. Pharmacol. Toxicol. Methods, 2008, 57(2), 85-91.
56. Bauer, M.; Langer, O.; Dal-Bianco, P.; Karch, R.; Brunner, M.; Abrahim, A.; Lanzenberger, R.; Hofmann, A.; Joukhadar, C.; Carminati, P.; Ghirardi, O.; Piovesan, P.; Forloni, G.; Corrado, M.E.; Lods, N.; Dudczak, R.; Auff, E.; Kletter, K.; Muller, M. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin. Pharmacol. Ther., 2006, 80(3), 216-227.
57. Bergstrom, M.; Yates, R.; Wall, A.; Kagedal, M.; Syvanen, S.; Langstrom, B. Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data. J. Pharmacokinet. Pharmacodyn., 2006, 33(1), 75-91.
58. Kegeles, L.S.; Slifstein, M.; Frankle, W.G.; Xu, X.; Hackett, E.; Bae, S.A.; Gonzales, R.; Kim, J.H.; Alvarez, B.; Gil, R.; Laruelle, M.; Abi-Dargham, A. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology, 2008, 33(13), 3111-3125.
59. Grunder, G.; Fellows, C.; Janouschek, H.; Veselinovic, T.; Boy, C.; Brocheler, A.; Kirschbaum, K.M.; Hellmann, S.; Spreckelmeyer, K.M.; Hiemke, C.; Rosch, F.; Schaefer, W.M.; Vernaleken, I. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am. J. Psychiatry, 2008, 165(8), 988-995.
60. Mamo, D.; Graff, A.; Mizrahi, R.; Shammi, C.M.; Romeyer, F.; Kapur, S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry, 2007, 164(9), 1411-1417.
61. Kornman, K.S. Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am. J. Clin. Nutr., 2006, 83(2), 475S-483S.
62. Pugliese, F.; Gaemperli, O.; Kinderlerer, A.R.; Lamare, F.; Shalhoub, J.; Davies, A.H.; Rimoldi, O.E.; Mason, J.C.; Camici, P.G. Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J. Am. Coll. Cardiol., 2010, 56(8), 653-661.
63. Zerizer, I.; Tan, K.; Khan, S.; Barwick, T.; Marzola, M.C.; Rubello, D.; Al-Nahhas, A. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur. J. Radiol., 2010, 73(3), 504-509.
64. van der Vaart, M.G.; Meerwaldt, R.; Slart, R.H.; van Dam, G.M.; Tio, R.A.; Zeebregts, C.J. Application of PET/SPECT imaging in vascular disease. Eur. J. Vasc. Endovasc. Surg., 2008, 35(5), 507-513.
65. Stumpe, K.D.; Strobel, K. Osteomyelitis and arthritis. Semin. Nucl. Med., 2009, 39(1), 27-35.
66. Vaglio, A.; Versari, A.; Fraternali, A.; Ferrozzi, F.; Salvarani, C.; Buzio, C. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum., 2005, 53(1), 122-125.
67. Rudd, J.H.; Myers, K.S.; Bansilal, S.; Machac, J.; Pinto, C.A.; Tong, C.; Rafique, A.; Hargeaves, R.; Farkouh, M.; Fuster, V.; Fayad, Z.A. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J. Nucl. Med., 2008, 49(6), 871-878.
68. Zhou, Z.; Kozlowski, J.; Goodrich, A.L.; Markman, N.; Chen, D.L.; Schuster, D.P. Molecular imaging of lung glucose uptake after endotoxin in mice. Am. J. Physiol Lung Cell Mol. Physiol, 2005, 289(5), L760-L768.
69. Stelljes, M.; Hermann, S.; Albring, J.; Kohler, G.; Loffler, M.; Franzius, C.; Poremba, C.; Schlosser, V.; Volkmann, S.; Opitz, C.; Bremer, C.; Kucharzik, T.; Silling, G.; Schober, O.; Berdel, W.E.; Schafers, M.; Kienast, J. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood, 2008, 111(5), 2909-2918.
70. Roivainen, A.; Parkkola, R.; Yli-Kerttula, T.; Lehikoinen, P.; Viljanen, T.; Mottonen, T.; Nuutila, P.; Minn, H. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum., 2003, 48(11), 3077-3084.
71. Kato, K.; Schober, O.; Ikeda, M.; Schafers, M.; Ishigaki, T.; Kies, P.; Naganawa, S.; Stegger, L. Evaluation and comparison of 11Ccholine uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(10), 1622-1628.
72. Lamare, F.; Hinz, R.; Gaemperli, O.; Pugliese, F.; Mason, J.C.; Spinks, T.; Camici, P.G.; Rimoldi, O.E. Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT. J. Nucl. Med., 2011, 52(1), 33-39.
73. Nahrendorf, M.; Keliher, E.; Panizzi, P.; Zhang, H.; Hembrador, S.; Figueiredo, J.L.; Aikawa, E.; Kelly, K.; Libby, P.; Weissleder, R. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC. Cardiovasc. Imaging, 2009, 2(10), 1213-1222.
74. Nahrendorf, M.; Zhang, H.; Hembrador, S.; Panizzi, P.; Sosnovik, D.E.; Aikawa, E.; Libby, P.; Swirski, F.K.; Weissleder, R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation, 2008, 117(3), 379-387.
75. Jarzyna, P.A.; Gianella, A.; Skajaa, T.; Knudsen, G.; Deddens, L.H.; Cormode, D.P.; Fayad, Z.A.; Mulder, W.J. Multifunctional imaging nanoprobes. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2(2), 138-150.